Paul Haluska, Jr., MD, PhD PERSONAL INFORMATION · Paul Haluska, Jr., MD, PhD PERSONAL INFORMATION...
35
Curriculum Vitae and Bibliography Paul Haluska, Jr., MD, PhD PERSONAL INFORMATION Place of Birth: Elizabeth, NJ Citizenship: United States Work Address: Merck Corporation 126 E. Lincoln Ave Rahway, New Jersey 07065 732-594-9106 email Address: [email protected] Home Address: 80 Randall Road Princeton, New Jersey 08540 Additional Information: Married, Spouse - Vanessa Fell Haluska Children - Luke Andrew Haluska and Elise Marie Haluska PRESENT ACADEMIC RANK AND POSITION Consultant - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota 06/24/2006 - 2015 Deputy Director - Mayo Clinic Phase I Program 05/29/2009 - 2015 Assistant Professor of Pharmacology - College of Medicine, Mayo Clinic 12/01/2009 - 2015 Associate Professor of Oncology - College of Medicine, Mayo Clinic 6/2011- 2015 Co-Director – Mayo Clinic Phase I Program 1/2014 – 1/2015 Director – Mayo Clinic Phase I Program 1/2015 – 4/2015 Global Director of Scientific Affairs, Oncology- Global Center for Scientific Affairs, Merck Research Labs 4/2015 – Present EDUCATION College of Arts and Sciences, Indiana University, Bloomington BS, Biochemistry 1988 - 1992 Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey MD/PhD, M.D., Ph.D. Program 1993 - 2000 Graduate School of Biomedical Sciences/UMDNJ-Robert Wood Johnson Medical School, Rutgers The State University of New Jersey PhD, Pharmacology 1995 - 1998 Internal Medicine Program, Clinical Investigator Program, Mayo Graduate School of Medicine Residency, Internal Medicine 2000 - 2003 Medical Oncology Fellowship Program, Clinical Investigator Program, Mayo Graduate School of Medicine Fellowship, Medical Oncology 2003 - 2006 BOARD CERTIFICATION(S) American Board of Internal Medicine Internal Medicine 2003
Transcript of Paul Haluska, Jr., MD, PhD PERSONAL INFORMATION · Paul Haluska, Jr., MD, PhD PERSONAL INFORMATION...
Curriculum Vitae and Bibliography
Paul Haluska, Jr., MD, PhD
PERSONAL INFORMATION
Place of Birth: Elizabeth, NJ
Citizenship: United States
Work Address:
Merck Corporation 126 E. Lincoln Ave Rahway, New Jersey 07065 732-594-9106
email Address:
Home Address:
80 Randall Road Princeton, New Jersey 08540
Additional Information:
Married, Spouse - Vanessa Fell Haluska Children - Luke Andrew Haluska and Elise Marie Haluska
PRESENT ACADEMIC RANK AND POSITION
Consultant - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota
06/24/2006 - 2015
Deputy Director - Mayo Clinic Phase I Program 05/29/2009 - 2015
Assistant Professor of Pharmacology - College of Medicine, Mayo Clinic
12/01/2009 - 2015
Associate Professor of Oncology - College of Medicine, Mayo Clinic 6/2011- 2015
Co-Director – Mayo Clinic Phase I Program 1/2014 – 1/2015
Director – Mayo Clinic Phase I Program 1/2015 – 4/2015
Global Director of Scientific Affairs, Oncology- Global Center for Scientific Affairs, Merck Research Labs
4/2015 – Present
EDUCATION
College of Arts and Sciences, Indiana University, Bloomington BS, Biochemistry
1988 - 1992
Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey MD/PhD, M.D., Ph.D. Program
1993 - 2000
Graduate School of Biomedical Sciences/UMDNJ-Robert Wood Johnson Medical School, Rutgers The State University of New Jersey PhD, Pharmacology
1995 - 1998
Internal Medicine Program, Clinical Investigator Program, Mayo Graduate School of Medicine Residency, Internal Medicine
2000 - 2003
Medical Oncology Fellowship Program, Clinical Investigator Program, Mayo Graduate School of Medicine Fellowship, Medical Oncology
2003 - 2006
BOARD CERTIFICATION(S)
American Board of Internal Medicine
Internal Medicine 2003
Medical Oncology 2006
LICENSURE
Minnesota 43661
HONORS/AWARDS
Glaxo Wellcome Oncology Clinical Research Scholar Award - American Association for Cancer Research Workshop
1997
New Jersey Cancer Research Award for Scientific Excellence - Rhone-Poulenc Rorer Oncology
1998
Clinician Investigator - General Mills Foundation 2003
Loan Repayment Program - National Institutes of Health 2003 - 2005
Chief Resident - Mayo Graduate School of Medicine-Clinical Investigator Program
2003 - 2005
Merit Award - American Society of Clinical Oncology 2004
Methods in Clinical Cancer Research Participant - American Society of Clinical Oncology/American Association for Cancer Research Workshop
2004
Molecular Biology in Clinical Oncology Participant - American Association for Cancer Research/American Society of Clinical Oncology Workshop
2005
Paul Calabresi Program Career Development Award - K12 - National Cancer Institute
2006
Young Investigator Award - American Society of Clinical Oncology 2006
Loan Repayment Program - National Institutes of Health 2007 - 2010
Mayo Clinic Breast SPORE Career Development Award - Mayo Clinic 2007 - 2009
Mayo Clinic Ovarian SPORE Career Development Award - Mayo Clinic 2009 - 2011
PREVIOUS PROFESSIONAL POSITIONS AND MAJOR APPOINTMENTS
Assistant Professor of Oncology - College of Medicine, Mayo Clinic 04/01/2006 - 2011
Senior Associate Consultant - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota
07/01/2006 - 06/23/2009
PROFESSIONAL & COMMUNITY MEMBERSHIPS, SOCIETIES AND SERVICES (*indicates office held)
Professional Memberships & Services
American Association for Cancer Research
*Member
2004 - Present
Career Development Committee
*Member
2004 - 2007
Publications Committee
*Member 2004 - 2007
Clinician Investigator Committee
*Member 2003 - 2005
Mayo Clinic Fellows Association
*Member 2000 - 2006
Minnesota Medical Association
*Member 2000 - 2015
Minnesota Ovarian Cancer Alliance
*Advisory Group Member
2007 - 2015
Oncology Research Committee
*Member 2003 - 2004
NCI Investigational Drug Steering Committee
* Signal Transduction Task Force Member 2009 - 2013
* Full Member
2014- 2015
ECCO/ESMO/AACR/EORTC Flims Methods in Clinical Cancer Research, Faculty
2013- Present
Study Section, Department of Defense
* Breast Cancer Research Program, Team Award Panel 2010 - 2013
* Breast Cancer Research Program, Transformative Visionary Award and Collaborative Innovator Award Panel
2011
Study Section, Susan G. Komen For The Cure
* Post-Doctoral Fellow Review Panel
2011 - 2012
Gynecologic Oncology Group (GOG)
* Developmental Therapeutics Committee, Member
2012 - 2015
Study Section, National Institutes of Health
* DMP (Drug Metabolism and Pharmacology), Ad hoc member 2013 - 2014
* MMTR (Mouse Models for Translational Research, Chair
2014 - Present
American Society of Clinical Oncology (ASCO)
* Member 2003 - Present
* Scientific Program Committee, Gynecological Cancers Track, Member 2012 - 2015
* Scientific Program Committee, Gynecological Cancers Track, Leader 2013 - 2014
* Cancer Education Committee, Member 2013 - 2015
EDUCATIONAL ACTIVITIES
Mentorship
Individual and Position
Timeframe & Description
Outcomes Current Status
Sagar, Malvika Research Trainee
2006 - 2007 Co-Author on manuscript
Resident, Pediatrics, Upland PA
Hou, Xiaonan Postdoctoral Fellow
2007 - Present Author on 3 presentations; 2 manuscripts, additional manuscripts pending, 2 industry contract funded
Converted to staff position as Senior Research Technician
Kahraman, Fatih Research Trainee
2008 (Summer) Completed Medical School Training in Turkey
Weroha, S. John 2008 - Present Published 2 Research phase of
Clinician Investigator manuscripts; author on 3 presentations; 2 successful grant application
Clinician Investigator Program in Oncology
Costello, Brian Oncology Fellow
2008 - Present Successful Grant Application- work related to grant ongoing
Staff- Division of Medical Oncology, Mayo Scholars Program
McKian, Kevin Oncology Fellow
2009 - Present Published manuscript Clinical Fellow in Hematology/Oncology
Duane, Sarah Summer Undergraduate Research Student
2009 (Summer) Graduated college (Carleton), currently applying to medical school
Wahner-Hendrickson, Andrea Clinician Investigator
2009 - Present 3 manuscripts published
In clinical component of Clinician Investigator Program in Hematology/Oncology
Farzan, Thahir Gynecological Oncology Fellow
2009 - 2010 Manuscript co-autors under consideration.
Completed fellowship; Practicing in Texas as Gynecological oncologist
Glaser, Gretchen Gynecological Oncology Fellow
2010 - 2011 Two manuscripts in development, one just submitted to Gynecologic Oncology
Completed fellowship; Practicing in Virginia as Gynecological oncologist
Jacob, Kristina Gynecological Oncology Fellow
2011 - 2012 Two first author manuscripts pending
Clinical component of Gynecological Oncology Fellowship
Becker, Marc Post-Doctoral Fellow
2010 - Present 2 First Author Publications and third pending, multiple additional co-authors, Pilot Grant Awards, T32 Awardee
Post-doctoral Fellow
Enderica Gonzalez, Sergio Visiting Medical Student (Ecuador)
2011 - 2012 First author and 2 secondary co-author manuscripts pending
Finishing Medical School
Al Hilli, Mariam Gynecological Oncology Fellow
2012-2013 First author manuscript in development, co-author on 2 additional manuscripts, Industry contract funded.
Clinical component of Gynecological Oncology Fellowship
Madde, Ankitha High School Honors Student
2013 Completed Project Characterizing BRCA mutation in ovarian tumor
Attending college- University of Pittsburgh
McKinstry, Sarah Research Trainee
2012-2013 First author manuscript in development
In Epidemiology graduate program at Emory.
Kumar, Amanika Gynecological Oncology Fellow
2013-Present Started July 2013
Tienchaiananda, Piyawan, Research Fellow
2013-2015 Started May 2013
Bocanega, Brandon High School Honors
2013 Started September 2013
Student
Zayed, Amira Research Fellow
2013
Lodhia, Kunal Research Fellow
2014
INSTITUTIONAL/DEPARTMENTAL ADMINISTRATIVE RESPONSIBILITIES, COMMITTEE MEMBERSHIPS AND OTHER ACTIVITIES (* indicates office held)
Mayo Clinic
Mayo Clinic Cancer Center, Concept Review Committee, Member
2004 - 2005
Shared Resource Advisory Committee 2007 - 2014
BAP User Oversight Committee 2007 - 2014
Mayo Clinic Cancer Center, Scientific Review Committee, Member 2011 - 2015
IACUC Committee, Member 2015
PRESENTATIONS
International
The IGF-1R/IR inhibitor, BMS-554417 has in vitro and in vivo activity. Haluska P, Carboni J, Loegering D, Lee F, Saulnier M, Frennesson D, Attar R, Kalli K, Conover C, Kaufmann S, Gottardis M, Erlichman C. Poster Presentation The Role of the IGF System in Cancer Taormina, Italy
11/10/2005 - 11/12/2005
Hormonal Adjuvancy Invited Oral Presentation VI International Symposium State of the Art in the management of Breast Cancer Lima, Peru
09/15/2006 - 09/16/2006
Hormonal Therapy in Metastatic Breast Cancer Invited Oral Presentation VI International Symposium State of the Art in the management of Breast Cancer Lima, Peru
09/15/2006 - 09/16/2006
HER receptor signaling confers resistance to the insulin-like growth factor 1 receptor inhibitor, BMS-536924. Paul Haluska, Joan M. Carboni, Cynthia TenEyck, Ricardo M. Attar, Xiaonan Hou, Chunrong Yu, Malvika Sagar, Tai W. Wong, Marco M. Gottardis, and Charles Erlichman. Poster Presentation Fourth International Congress of the GRS and the IGF Society Genova, Italy
09/16/2008 - 09/20/2008
Bi-directional resistance pathways relevant to anti-IGF-1R targeted therapy: Pathway to Clinical Development. Oral Presentation Fourth International Congress of the GRS and the IGF Society Genova, Italy
09/16/2008 - 09/20/2008
The insulin-like growth factor pathway-the key to overcoming resistance to cancer therapy? Oral Presentation 2nd World Conference of Magic Bullets Nurnberg, Germany
10/03/2008 - 10/05/2008
Novel Targeted Therapy Invited Oral Presentation The 3rd Middle East Best of CTRC-AACR San Antonio Breast Cancer Symposium Riyadh, Saudi Arabia
01/15/2009 - 01/20/2009
Molecular Profiling for Guiding Therapeutics Invited Oral Presentation The 3rd Middle East Best of CTRC-AACR San Antonio Breast Cancer Symposium Riyadh, Saudi Arabia
01/15/2009 - 01/20/2009
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory adrenocortical carcinoma Haluska P, Worden F, Olmos D, Yin D, Schteingart, Batzel G, Paccagnella ML, de Bono J, Gualberto A, Hammer G. Poster Presentation Targeted Anticancer Therapies (TAT) Amsterdam, Netherlands
03/22/2009 - 03/24/2009
Phase II Trial of Lapatinib in Combination with Weekly Topotecan in Patients with Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma Oberg A, Dakhil S, Allen Ziegler K, Rowland K, Hartmann L, Moore D, Keeney G, Peethambaram P, Haluska P. Poster Presentation Targeted Anticancer Therapies (TAT) Amsterdam, Netherlands
03/22/2009 - 03/24/2009
Biomarkers in Anti-IGF-1R Targeted Therapy Invited Oral Presentation Oncology Advisory Board Meeting, Hoffman-La Roche Munich, Germany
04/2009
Current IGF-1R Targeted Clinical Studies in Breast Cancer Invited Oral Presentation Oncology Advisory Board Meeting, Hoffman-La Roche Munich, Germany
04/2009
Insulin Like Growth Factor Signaling and Cancer Invited Oral Presentation Nanjing University- School of Medicine Nanjing, China
10/12/2009
Molecular Targeted Therapy in Ovarian Cancer (Terapia blanco molecular en Cancer de Ovario) Invited Oral Presentation Seventh Congress of Medical Oncology: Towards Personalized Oncology (VII Congresso Peruano de Oncologia Medica: Hacia La Oncologia Personalizada) Cusco, Peru
08/25/2010 - 08/28/2010
Platinum-Resistant Ovarian Cancer: New Alternatives (Cancer de Ovario Platino resistente: Nuevas alternativas) Invited Oral Presentation Seventh Congress of Medical Oncology: Towards Personalized Oncology (VII Congresso Peruano de Oncologia Medica: Hacia La Oncologia Personalizada) Cusco, Peru
08/25/2010 - 08/28/2010
Chemotherapy for Patients with Ovarian Cancer III Curso Internacional de Oncologia Y Enfermeria Oncologica Guayaquil, Ecuador
11/18/2010 - 11/21/2010
Chemotherapy for Patients with Cervical Cancer III Curso Internacional de Oncologia Y Enfermeria Oncologica Guayaquil, Ecuador
11/18/2010 - 11/21/2010
Phase I Trial of Figitumumab and Pegvisomant in Patients with Advanced Solid Tumors Haluska P, Dudek AZ, Bono P, Sleight B, Joensuu H, Juergens H, and Pollak M. Poster Presentation Targeted Anticancer Therapies (TAT) Paris, France
03/07/2011 - 03/09/2011
Breast Cancer – Entering the Molecular Age Invited Oral Presentation 2012 Ramathibodhi-Mayo Joint Conference Bangkok, Thailand
02/10/2012 - 02/11/2012
Advancing the treatment of HER-2 positive breast cancer Invited Oral Presentation 2012 Ramathibodhi-Mayo Joint Conference Bangkok, Thailand
02/10/2012 - 02/11/2012
Ovarian Avatar Project: A model system for individualizing ovarian cancer therapy. Haluska P, Oberg AL, Glaser G, Gonzalez SE, Becker MA, Jacob KA, Pennil CC, Fink SR, Kalli KR, Swisher EM, Jenkins RB, Sarkaria JN, Karlan BY, Weroha SJ Poster Presentation 10th International Congress on Targeted Anticancer Therapies (TAT) Amsterdam, The Netherlands
03/08/2012 - 03/10/2012
Gynecologic cancer case presentations Roundtable discussions Problems of Oncology: Opinions from Two Continents Kaliningrad, Russian Federation
10/4/2012 - 10/5/2012
Adjuvant therapy for resected ovarian cancer Management of metastatic ovarian cancer Management of cervix cancer Invited Oral Presentation Problems of Oncology: Opinions from Two Continents Kaliningrad, Russian Federation
10/4/2012 - 10/5/2012
Phase I study of figitumumab and pegvisomant in patients with advanced solid tumors Paul Haluska, Uta Dirksen, Arkadiusz Z. Dudek, Petri Bono, Heikki Joensuu, Heribert Juergens, Barbara Sleight, and Michael Pollak Oral Presentation The 6th International Congress of the GRS and IGF Society Munich, Germany
10/17/2012 - 10/20/2012
A Phase 1 Study of MEDI-573, an Investigational Monoclonal Antibody That Targets IGF-I and IGF-II: Safety, Pharmacokinetics, and Antitumor Activity in Adults With Advanced Solid Tumors Paul Haluska, Michael Menefee, Elizabeth Plimack, Jonathan Rosenberg,
11/6/2012 - 11/9/2012
Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Jaye Viner, Patricia LoRusso Poster Presentation 24th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics Dublin, Ireland
Ovarian Avatar Models Predictive of Platinum Response In Ovarian Cancer Patients Weroha SJ, Becker MA, Harrington SC, Goodman K, Gonzalez SE, Al Hilli M, Butler KA, Kalli KR, Oberg AL and Haluska P. Oral Presentation 11th International Congress on Targeted Anticancer Therapies Paris, France
3/4/2013 - 3/6/2013
Role of Pharmacokinetics and Pharmacodynamics in Clinical Trials Methods in Clinical Cancer Research Films, Switzerland
06/20/2014 – 06/28/2014
National
Sequential camptothecin and etoposide in the treatment of refractory malignancies Toppmeyer D, Haluska P, Li X-G, Goodin S, Orlick M, Aisner J, Rubin EH Annual Retreat on Cancer Research New Jersey
05/31/1996
Identification of Human Topoisomerase I-binding Proteins Using the Two-Hybrid System in S. cerevisiae Haluska P and Rubin EH Annual Retreat on Cancer Research New Jersey
05/31/1996
Analysis of topoisomerase I and II protein levels in a clinical trial of sequential camptothecin and etoposide Saleem A, Toppmeyer D, Gupta E, Zamek R, Much J, Ibrahim N, Bindi M, Haluska P, Li X-G, Goodin S, Aisner J, Natelson E, Giovanella B and Rubin EH Poster Presentation The Seventh Conference on DNA Topoisomerases in Therapy- NYU Medical Center and The Kaplan Cancer Center
10/21/1996 - 10/24/1996
Helicase Binding by the Amino Terminus of Human Topoisomerase I Haluska P and Rubin EH Oral Presentation 1997 AACR Annual Meeting San Diego, California
04/12/1997 - 04/16/1997
Identification of Novel Topoisomerase Binding Proteins Invited Plenary Speaker for presentation of abstract Annual Retreat on Cancer Research New Jersey
05/30/1997
A Phase I Pharmacokinetic and Pharmacodynamic Study of Camptothecin and Etoposide in Patients with Advanced Malignancies Toppmeyer D, Gupta E, Saleem A, Zameck R, Much J, Ibrahim N, Bindi H, Haluska P, Li XG, Goodin S, Aisner J, Natelson N, Giovanella B, Rubin EH Annual Retreat on Cancer Research New Jersey
05/30/1997
A Novel RS Protein Binds Human Topoisomerase I Haluska P, Saleem A, Rubin EH Poster Presentation 1998 AACR Annual Meeting
03/28/1998 - 04/01/1998
Characterization of a Novel Topoisomerase I-Binding Protein Haluska P, Saleem A, Rubin EH Annual Retreat on Cancer Research New Jersey
05/29/1998
Identification of a novel protein that binds to human topoisomerase I Rasheed Z, Haluska P, Saleem A, Rubin EH Poster Presentation 1999 AACR Annual Meeting
04/10/1999 - 04/14/1999
Interesting Case Presentations- Oral Presentation Haluska P Big Sky Oncology Update 2003 Big Sky, Montana
07/24/2003 - 07/26/2003
A phase I trial of gemcitabine, 17-allylaminogeldanamycin (17-AAG) and cisplatin in solid tumor patients Haluska P, Toft D. O., Steinmetz S. M., Furth A., Mandrekar S., Stensgard B. A., McCollum A. K., Hanson L. J., Adjei A. A., Erlichman C Poster Presentation 2004 ASCO Annual Meeting New Orleans, Louisiana
06/05/2004 - 06/08/2004
SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one inhibitors of the IGF-1 receptor kinase with in vivo antitumor activity Saulnier MG, Velaparthil U, Frennesson1 DB, Liu P, Zimmermann K, Sang X, Eummer J, Bedingfield K, Lee FT, Carboni JM, Vyas DM, Haluska P, Loegering DA, Kaufmann SH, Erlichman C, Attar R, Gottardis G, and Wittman M. Proceedings of the 229th National Meeting of the American Chemical Society San Diego, California
03/13/2005 - 03/17/2005
BMS-554417, an Inhibitor of the Insulin-Like Growth Factor I Receptor and Insulin Receptor, Inhibits Proliferation and Induces Mitochondrial Pathway-Mediated Apoptosis in Cancer Cell Lines Haluska P, Carboni JM, Loegering DA, Lee FY, Saulnier M, Frennesson D, Attar R, Kalli KR, Conover CA, Mandrekar SJ, Kaufmann SH, Gottardis M and Erlichman C Poster Presentation 2005 AACR Annual Meeting Anaheim, California
04/16/2005 - 04/20/2005
BMS-554417, an Inhibitor of the Insulin-Like Growth Factor I Receptor and Insulin Receptor, Inhibits Proliferation and Induces Mitochondrial Pathway-Mediated Apoptosis in Cancer Cell Lines Haluska P, Carboni JM, Loegering DA, Lee FY, Saulnier M, Frennesson D, Attar R, Kalli KR, Conover CA, Mandrekar SJ, Kaufmann SH, Gottardis M and Erlichman C Poster Presentation Gordon Conference-Molecular Therapeutics of Cancer New London, New Hampshire
07/17/2005 - 07/22/2005
Clinical Case Studies in Supportive Care Options 06/02/2006 - 06/06/2006
Historical overview of the treatment of lung and colorectal cancers and supportive care options. Invited Oral Presentation 2006 ASCO Annual Meeting Atlanta, Georgia
The Refractory Ovarian Cancer Patients: What are the Causes of Resistance to Chemotherapy Invited Oral Presentation 16th Annual Mayo Clinic Hematology/Oncology Reviews; 8th Annual Fellows' Research Presentations and 1st Cancer Research Review Amelia Island, Florida
08/01/2006 - 08/05/2006
Co-inhibition of the IGF-1R and HER family of receptors stimulates synergistic cell death in human ovarian cancer cells. Paul Haluska, Chunrong Yu, Joan M. Carboni, Diane C. Soeffker, Tai W. Wong, Mark G. Saulnier, Ricardo M. Attar, Mark Wittman, Scott H. Kaufmann, Marco Gottardis, Charles Erlichman Poster Presentation 2007 AACR Annual Meeting Los Angeles, California
04/14/2007 - 04/18/2007
Apoptotic and anti-proliferative effects of the dual insulin-like growth factor-1 (IGF-1R)/insulin receptor inhibitor, BMS 536924, in acute myelogenous leukemia. Andrea E. Wahner Hendrickson, Judith E. Karp, Joan Carboni, Ricardo M. Attar, B. Douglas Smith, Mark Whittman, Marco Gottardis, Paul J. Haluska, Scott H. Kaufmann. Poster Presentation 2007 AACR Annual Meeting Los Angeles, California
04/14/2007 - 04/18/2007
Phase I dose escalation study of the anti-IGR monoclonal antibody CP-751,871 in patients with refractory solid tumors P. Haluska, H. M. Shaw, G. N. Batzel, L. R. Molife, A. A. Adjei, T. A. Yap, M. L. Roberts, D. Yin, A. Gualberto, J. S. de Bono Poster Presentation 2007 ASCO Annual Meeting Chicago, Illinois
06/01/2007 - 06/05/2007
Circulating tumor cells expressing the insulin growth factor-1 receptor (IGF-1R); Method of detection, incidence and potential applications. J. S. de Bono, A. Adjei, G. Attard, M. Pollak, P. Fong, P. Haluska, L. Roberts, D. Chainese, L. Terstappen, A. Gualberto Oral Presentation 2007 ASCO Annual Meeting Chicago, Illinois
06/01/2007 - 06/05/2007
Insulin-like growth factor binding protein-5 is overexpressed in breast cancer cells resistant to IG-1R inhibition Paul Haluska, Cynthia Ten Eyck, Joan M Carboni, Yan W Asmann, Mark G. Saulnier, David Frennesson, Ricardo M Attar, Cheryl A Conover, Mark D Wittman, Marco Gottardis and Charles Erlichman Poster Presentation 15th SPORE Investigators' Workshop Baltimore, Maryland
07/07/2007 - 07/10/2007
Co-inhibition of the IGF-1R and HER family of receptors stimulates synergistic cell death in human ovarian cancer cells. Haluska P, Yu C, Carboni J, Soeffker D, Wong T, Saulnier M, Attar R,
07/22/2007 - 07/27/2007
Wittman M, Kaufmann S, Gottardis M, Erlichman C Poster Presentation Molecular Therapeutics of Cancer Gordon Research Conference New London, New Hampshire
Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors. Olmos D, Molife R, Okuno S, Worden F, Hammer G, Yap T, Shaw H, Schuetze S, Roberts L, Gualberto A, de-Bono J, Haluska P Poster Presentation AACR-NCI-EORTC International Conference San Francisco, California
10/22/2007 - 10/26/2007
Breast Cancer Landscape Invited Oral Presentation Bristol Myers Squibb Advisory Board Meeting: IGF-1R Inhibitor Program New York, New York
12/03/2007
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. Discussant for Paper Matulonis U.A., Penson R.T., Campos, S.M., Lee, H., Lee J., Kendall D.L., Krasner C.N., Berlin S., Roche M. , Duska L.R., and Horowitz, N.S 39th Annual Meeting, Society of Gynecological Oncology Tampa, Florida
03/09/2008 - 03/12/2008
Phase I study of 17-allylamino-17 demethoxygeldanamycin (17-AAG), gemcitabine (Gem) and/or cisplatin (CDDP) in solid tumor patients. P. Haluska, B.A. Stensgard, R. Qin, S.J. Felten, G.N. Batzel, S.P. Ivy, D.O. Toft, C. Erlichman. Poster Presentation 6th International Symposium on Targeted Anticancer Therapies Bethesda, Maryland
03/20/2008 - 03/22/2008
Characterization of NSCLC patients responding to anti-IGF-IR therapy. Gualberto A, Melvin CL, Dean A, Ang AL, Reynolds JM, Lee AV, Terstappen LW, Haluska P, Lipton A, Karp DD. Oral Presentation 2008 ASCO Annual Meeting Chicago, Illinois
05/30/2008 - 06/03/2008
HER receptor signaling confers resistance to IGF-1R targeted therapy Paul Haluska, Joan M. Carboni, Cynthia TenEyck, Ricardo M. Attar, Xiaonan Hou, Chunrong Yu, Malvika Sagar, Tai W. Wong, Marco M. Gottardis and Charles Erlichman Poster Presentation 2008 ASCO Annual Meeting Chicago, Illinois
05/30/2008 - 06/03/2008
Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. Olmos D, Okuno S, Schuetze SM, Paccagnella ML, Yin D, Gualberto A, Worden FP, Haluska P, De Bono JS, Scurr M Oral Presentation 2008 ASCO Annual Meeting Chicago, Illinois
05/30/2008 - 06/03/2008
High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC.
05/30/2008 - 06/03/2008
Karp DD, Paz-Ares LD, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Gualberto A, Langer CJ Oral Presentation 2008 ASCO Annual Meeting Chicago, Illinois
Population pharmacokinetics of CP-751,871, a monoclonal antibody against IGF-1 receptor, in patients with multiple myeloma or solid tumors. Yin D, Paccagnella ML, Lacy MQ, De Bono JS, Haluska P, Gualberto A, Sharma A Poster Discussion Presentation 2008 ASCO Annual Meeting Chicago, Illinois
05/30/2008 - 06/03/2008
Phase I trial of Intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa). Galanis E, Hartmann LC, Cliby W, Peethambaram PP, Long HJ, Kaur JS, Haluska P, Sloan JA, Peng K, Russell SJ Poster Presentation 2008 ASCO Annual Meeting Chicago, Illinois
05/30/2008 - 06/03/2008
Gynecological Malignancies Session Chair 18th Annual Hematology/Oncology Reviews Amelia Island, Florida
08/04/2008 - 08/08/2008
New and Emerging Treatments in Ovarian Cancer: A 2008 Update. Invited Oral Presentation 18th Annual Hematology/Oncology Reviews Amelia Island, Florida
08/04/2008 - 08/08/2008
Management of HER2+ metastatic breast cancer: Current standard and novel approaches. Invited Oral Presentation 18th Annual Hematology/Oncology Reviews Amelia Island, Florida
08/04/2008 - 08/08/2008
BMS-536924 Invited Oral Presentation 10th Annual Targeted Therapies of the Treatment of Lung Cancer Santa Monica, CA
02/2009
Targeting IGF signaling in breast cancer to overcome resistance to hormonal therapy. Haluska P, Hou X, Carboni J, Macedo L, Harrington S, Attar R, Ingle J, Suman V, Brodie A, Gottardis M. Poster Presentation Gordon Research Conference Ventura, California
03/22/2009 - 03/27/2009
Insulin Receptor A isoform and erbB receptor up-regulated in response to IGF-1R targeted therapy. Harrington S, Hou X, Macedo L, Weroha J, Brodie A, Haluska P. Poster Presentation Gordon Research Conference Ventura, California
03/22/2009 - 03/27/2009
Hormonal therapies differentially enhance insulin receptor isoform A and 04/18/2009 - 04/22/2009
erbB receptor up-regulation in response to IGF-1R inhibitor MK-0646 in vivo. Hou X, Harrington S, Macedo L, Weroha J, Brodie A, Haluska P. Poster Presentation 100th Annual AACR Meeting 2009 Denver, Colorado
Combined estrogen signaling inhibition and IGF-1R/InsR inhibition with BMS-754807 in estrogen dependent breast cancer model has synergistic antitumor activity in vitro and in vivo. Hou X, Carboni J, Macedo L, Harrington S, Finckenstein F, Brodie A, Gottardis M. Haluska P, Poster Presentation 100th Annual AACR Meeting 2009 Denver, Colorado
04/18/2009 - 04/22/2009
Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. D. D. Karp, S. Novello, F. Cardenal, P. Haluska, L. J. Blakely, L. Garland, L. G. Paz-Ares, M. P. Dolled-Filhart, E. D. Johnson, A. Gualberto Poster Presentation 2009 ASCO Annual Meeting Orlando, Florida
05/29/2009 - 06/02/2009
Applying IGF Signaling to Current Breast Cancer Therapy Invited Oral Presentation Medimmune Meeting Gaithersburg, Maryland
06/04/2009
IGF-Signaling Blockade Overcomes Resistance to Hormonal Therapy in Metastatic Breast Cancer Models Oral Presentation TBCRC Meeting Dallas, Texas
07/16/2009
Gynecological Malignancies Session Chair 19th Annual Mayo Hematology/Oncology Reviews Amelia Island, Florida
07/30/2009 - 08/01/2009
New Therapies in GYN Management Invited Oral Presentation 19th Annual Mayo Hematology/Oncology Reviews Amelia Island, Florida
07/30/2009 - 08/01/2009
Advances in Gyn Malignancies 19th Annual Mayo Hematology/Oncology Reviews Amelia Island, Florida
08/2009
Complete IGF Signaling Blockade by the Dual-Kinase Inhibitor, BMS-754807, Is Sufficient To Overcome Tamoxifen and Letrozole Resistance In Vitro and In Vivo. Haluska P, Hou X, Huang F, Harrington SC, Greer A, Macedo LF, Brodie A, Evans DB, Carboni JM, Gottardis MM Poster Discussion San Antonio Breast Cancer Symposium San Antonio, TX
12/9/2009 - 12/13/2009
Low expression of insulin-like growth factor binding proteins predicts poor outcomes in ovarian cancer patients.
02/06/2010
Haluska P, Harrington SC, Farzan T, Winterhoff BJ, Goodman KM, Kalli KK, Gottfried KE AACR/JCA Joint Conference: Genomics, Epigenomics, and the Development of Novel Therapeutics Waikoloa, Hawaii
Review: San Antonio Breast Cancer Symposium Web-based seminar- Amgen Haluska P.
1/25/2010
BMS-754807 Invited Oral Presentation 10th Annual Targeted Therapies of the Treatment of Lung Cancer Santa Monica, CA
02/24/2010 - 02/24/2010
Phase I trial of the combined targeting of the Hedgehog (GDC-0449) and EGFR pathways (erlotinib) in pancreatic cancer. AACR 101st Annual Meeting 2010 Washington, District of Columbia
04/19/2010
Regulation of hormone resistant breast cancer by IGF and insulin system signaling Haluska P (oral plenary presentation) 2010 Breast SPORE Roundtable Meeting National Harbor, Maryland
05/20/2010
N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer Haluska P, Reinhiolz MM, Dueck AC, Linden HM, Lingle WL, Bernath AM, Arbushites MC, Youssoufian H, Chen HX, Perez EA (Abstract #TPS129) Onconet Steering Committee Meeting 2010 ASCO Annual Meeting Chicago, Illinois
06/06/2010
Phase I trial of dasatinib (D) and lapatinib (L). J Clin Oncol 28:15s, 2010 (suppl; abstr 2610). Co-authors on poster: Erlichman C, Menefee ME, Northfelt DW, Qin R, Reid JM, Oursler M, Marks R, Molina JR, Koch K 2010 ASCO Annual Meeting Chicago, Illinois
06/07/2010
Development Therapeutics – Clinical Pharmacology and Immunotherapy. Erlichman C, Menefee M, Northfelt D, Qin R, Oursler MJ, Marks R, Haluska P, Molina J, Koch KM. Poster Presentation 2010 ASCO Annual Meeting Chicago, Illinois
6/7/2010
N0733: Phase II trial of capecitabine and lapatinib +/- cixutumumab in HER2 positive breast cancer. Haluska P, Reinholz MM, Dueck AC, Linden HM, Lingle WL, Bernath AM, Arbushites MC, Youssoufian H, Chen HX, Perez A. Trials in Progress Poster Presentation 2010 ASCO Annual Meeting Chicago, Illinois
6/7/2010
IGF-1 Inhibition in the treatment of Breast Cancer CME presentation, St. Vincent Hospital Green Bay, WI
08/06/2010
Chemotherapy (Standard and New) Invited Oral Presentation Mayo Clinic Arizona Mayo Clinic Multidisciplinary Update in Breast Diseases Scottsdale, AZ
11/12/2010
Approved Targeted Therapies Invited Oral Presentation Mayo Clinic Arizona Mayo Clinic Multidisciplinary Update in Breast Diseases Scottsdale, AZ
11/12/2010
Endocrine Therapies Invited Oral Presentation Mayo Clinic Arizona Mayo Clinic Multidisciplinary Update in Breast Diseases Scottsdale, AZ
11/13/2010
BMS-754807 Invited Oral Presentation 11th Annual Targeted Therapies of the Treatment of Lung Cancer Santa Monica, CA
02/23/2011
Insulin Receptor Isoform A is the Predominant Isoform in Breast Cancer Patients Poster Presentation Gordon Conference: Insulin-Like Growth Factors in Physiology & Disease Ventura, CA
02/27/2011 - 3/4/2011
The Role of InsR Isoforms and IGFBPs in Sensitivity to IGF-1R Targeting Invited Oral Presentation Spring 2011 NCI CTEP Early Drug Development Meeting Bethesda, MD
03/14/2011
Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. Haluska P, Dhar A, Hou X, Huang F, Nuyten DSA, Park JS, Brodie AH, Ingle JN, Carboni JM, Gottardis MM, Wolff AC, Finckenstein FG. Trials in Progress Poster Presentation 2011 ASCO Annual Meeting Chicago, Illinois
06/06/2011
IGF Targeting in Cancer: Trials and Tribulations Invited Oral Presentation 2011 Endocrine Society Annual Meeting Boston, Massachusetts
06/06/2011
Regulation of Hormone-resistant Breast Cancer by IGF and Insulin System Signaling. Haluska P, Hou X, Dhar A, Yee D, Suman VJ, Harrington SC, Finckenstein F, Ingle JN. Poster Discussion NCI Translational Science Meeting 2011 Washington, DC
07/28/2011
Current Status of PARP inhibitors in Ovarian Cancer Invited Oral Presentation NCI Translational Science Meeting 2011 Washington, DC
07/28/2011
IGF Signaling as a Mechanism of Resistance to Hormonal Therapy in Breast Cancer Invited Oral Presentation Women’s Cancer/Cell Signaling Lecture Series University of Minnesota Minneapolis, Minnesota
08/30/2011
Mayo Ovarian Living Tumor Bank as a Drug Development Tool Invited Oral Presentation WCRC Seminar Series University of Pittsburgh Cancer Institute Pittsburgh, PA
09/08/2011
MEDI-573--a novel approach to IGF-1R and IR-A signaling inhibition by blocking IGF ligands: Phase 1 PK/PD, safety data, and disease linkage studies in breast cancer P. Haluska, J. Huang, B. Lam, X. Chen, W. Huang, P. LoRusso, M.E. Menefee, T. LaVallee, Y. Yao, J. Viner Poster Presentation ASCO Breast Cancer Symposium San Francisco, CA
09/09/2011
MEDI-573—a novel approach to IGF-1R and IR-A signaling inhibition by blocking IGF ligands: Phase 1 PK/PD, safety data, and disease linkage studies in breast cancer Oral Presentation P. Haluska, J. Huang, B. Lam, X. Chen, W. Huang, P. LoRusso, M.E. Menefee, T. LaVallee, Y. Yao, J. Viner ASCO Breast Cancer Symposium San Francisco, CA
09/09/2011
IGF Signaling as a Target in Cancer- Trials and Tribulations Invited Oral Presentation Cancer Center Grand Rounds: http://videos.med.wisc.edu/videos/36384 University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, WI
11/2/2011
IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors Poster Presentation Becker MA, Hou X, Harrington SC, Carboni JM, Gottardis MM, Haluska P. San Antonio Breast Cancer Symposium San Antonio, Texas
12/6/2011 - 12/11/11
BMS-754807 Invited Oral Presentation 11th Annual Targeted Therapies of the Treatment of Lung Cancer Santa Monica, CA
02/22/2012 - 02/25/2012
Ovarian Avatar Project Invited Oral Presentation Visiting Professor Mayo Clinic - Jacksonville, Florida
2/1/2013
Systemic Therapies for Gynecological Malignancies Invited Oral Presentation Individualized Breast, Gynecologic, and Colon Cancer Management: New
2/15/2013 - 2/16/2013
Data and Updates Relevant to Patient Care Jacksonville, Florida
Anti-IGF ligand Antibodies Invited Oral Presentation 11th Annual Targeted Therapies of the Treatment of Lung Cancer Santa Monica, CA
2/21/2013 - 2/23/2013
In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer AACR Advances in Ovarian Cancer Research Miami, Florida Selected Oral Presentation by Mentee, Dr. Mariam AlHilli
09/18/2013 - 09/21/2013
Anti-IGF Ligand Antibody: BI836845 and MEDI-573 14th Annual Targeted Therapies of the Treatment of Lung Cancer Invited Oral Presentation Session Chair Santa Monica, CA
02/19/2014 – 02/20/2014
Of Mice and (Wo)men: The Ovarian Avatar Project Memorial Sloan Kettering Cancer Center Grand Rounds Oral Presentation New York, NY
05/20/2014
The Ovarian Avatar Project: Of Mice and (Wo)men Mayo Clinic Arizona Grand Rounds Oral Presentation Scottsdale, AZ
05/21/2014
The Mayo Ovarian Program: Of Mice and (Wo)men University of Illinois Grand Rounds Oral Presentation Chicago, IL
5/29/2014
Novel Targeting Approaches in Ovarian Cancer Oral abstract session Discussant Ovatars: Using Patient-Derived Xenografts for Selecting Best Therapies Educational session Invited Speaker Randomized Phase II Trial of Capecitabine and Lapatinib +/- IMC-A12 in Patients with HER2+ Breast Cancer Previously Treated with Trastuzumab and an anthracycline and/or a taxane, NCCTG N0733 (Alliance) Poster Presentation P. Haluska, A.M. Bernath Jr., K.V. Ballman, A.C. Dueck, H.M. Linden, M.P. Goetz, D.W. Northfelt, X. Hou, K.S. Tenner, P. Tienchaiananda, L.M. Flickinger, B. Chen, H.X. Chen, W.L. Lingle, C.M. Pellegrino, R.W. Sponzo, M.M. Reinholz, E.A. Perez, 2014 Annual ASCO Meeting Chicago, IL
05/20/2014 – 06/03/2014
Palliative chemotherapy approaches to recurrent disease and novel biologic therapies. ABS GYN School
07/14/2014
Invited Speaker Chicago, IL
Gynecologic Oncology 24th Annual Mayo Clinic Hematology/Oncology Review CME Course Invited Speaker Amelia Island, FL
08/08/2014
Novel strategies to target the C5 subclass of high-grade serous ovarian cancer using patient-derived xenografts. Poster Presentation 15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, Australia
11/09/2014
Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer Oral Presentation P Haluska, K Timms, M Al Hilli, Y Wang, A-R Hartmann, J Jones, A Gutin, Z Sangale, C Neff, J Lanchbury, L Rudolph-Owen, MA Becker, X Hou, S Agarwal and K Wilcoxen 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain 18-21 November 2014.
11/18/2014 – 11/21/2014
Regional
Non-surgical Free Intraperitoneal Air Allen RD, Haluska P, Bergstrom L Minnesota American College of Physician Annual Meeting Bloomington, Minnesota
10/25/2002
Postinfectious Glomerulonephritis & Furosemide-Induced Interstitial Nephritis Allen RD, Haluska P, Bergstrom L Minnesota American College of Physician Annual Meeting Bloomington, Minnesota
10/25/2002
Ovarian Cancer - Can We Do Better? Grand Rounds - St. Joseph's Hospital St. Paul, Minnesota
09/29/2006
Targeted Therapy Oral Presentation 5th Annual NCCTG Patient Advocate Symposium Rochester, Minnesota
06/11/2007 - 06/13/2007
Ovarian Cancer: Can We Do Better? Grand Rounds - Lake Region Health Care Hospital Fergus Falls, Minnesota
10/03/2007
Molecular Targeted Treatment Oral Presentation 6th Annual NCCTG Patient Advocate Symposium Rochester, Minnesota
06/09/2008 - 06/11/2008
Special Treatment for Triple Negative Disease and HER2 Positive Breast Cancer. Invited Oral Presentation Mayo Multidisciplinary Update in Breast Diseases Rochester, Minnesota
11/19/2009 - 11/21/2009
Breast Cancer-Entering the Molecular Age Invited Oral Presentation 2011 Current Issues in Cancer Care Conference: Innovative Approaches To Cancer Rochester, Minnesota
9/15/2011
Making Sense of Clinical Trials in Ovarian Cancer- “Why me, Why now?” Oral Presentation Minnesota Ovarian Cancer Alliance Sponsored Lecture Bloomington, Minnesota
10/20/2011
Chemoradiotherapy for Locally Advanced Cervical Cancer Oral Presentation Mayo Clinic Gynecology Oncology Conference Rochester, MN
1/7/2014
The AVATAR Project Oral Presentation Heme/Onc/BMT Professional Development Series Mayo Continuing Nursing Education Rochester, MN
3/11/2014 3/18/2014
Overexpression of IGF-2 in primary patient ovarian cancer tumorgrafts increases bowel and thoracic metastasis. Poster Presentation AACR Annual Meeting San Diego, CA
4/7/2014
Utilizing ER Target genes as biomarkers of endocrine response in serous ovarian carcinoma. Poster Presentation AACR Annual Meeting San Diego, CA
4/7/2014
Of Mice and (Wo)men: The Ovarian Avatar Project Oral Presentation Grand Rounds, Memorial Sloan Kettering Cancer Center. New York, NY
05/20/2014
Novel targeting approaches in ovarian cancer. Invited Discussant ASCO Annual Meeting Chicago, IL
05/31/2014
Ovatars: Using patient-derived xenografts for selecting best therapies. Invited Oral Presentation ASCO Annual Meeting Chicago, IL
05/31/2014
Randomized phase II trial of capecitabine and lapatinib +/- IMC-A12 in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane, NCCTG N0733 (Alliance) Poster Presentation ASCO Annual Meeting Chicago, IL
06/02/2014
Role of pharmacokinetics and pharmacodynamics in clinical trials Methods in Clinical Cancer Research Films, Switzerland
06/24/2014
Chemoradiotherapy for locally advanced cervical cancer. Gynecology Oncology Conference Mayo Clinic Rochester, MN
07/07/2014
Palliative chemotherapy approaches to recurrent disease and novel biologic therapies Invited Oral Presentation GYN School Chicago, IL
07/14/2014
Gynecologic Oncology Invited Oral Presentation 24th Annual Mayo Clinic Hematology/Oncology Review CME Course Amelia Island, FL
08/08/2014
Lessons learned from targeting the IGF-1R and implications for cancer prevention Invited Oral Presentation Thirteenth Annual AACR International Conference on Frontiers in Cancer Prevention Research New Orleans, LA
10/01/2014
The Mayo Ovarian Avatar Program: Of Mice and (Wo)men Keynote Speaker University of Alabama at Birmingham Comprehensive Cancer Center 17th Annual Research Retreat Birmingham, Alabama
10/06/2014
CLINICAL PRACTICE, INTERESTS, AND ACCOMPLISHMENTS
Ovarian cancer, Breast Cancer, Phase I clinical trials, Patient-derived xenografts
RESEARCH INTERESTS
Drug Development, Preclinical Research, Patient-Derived Xenografts, Ovarian Cancer, Breast Cancer
RESEARCH GRANTS AWARDED
Active Grants
Federal
Principle Investigator
R01 CA184502 (Haluska) National Cancer Institute (PQD5) Avatar-directed Treatment for Ovarian Cancer
05/13/14 – 05/12/18
Principle Investigator
UM1 CA186686-1 (Haluska) National Cancer Institute NCI Experimental Therapeutics- Clinical Trials Network with Phase 1 Emphasis
4/7/14-3/31/19
Project Co-Leader
P50 CA116201 (Ingle - PI) National Cancer Institute Mayo Clinic Breast Cancer SPORE “Project #3- Regulation of Hormone Resistant Breast Cancer by IGF and Insulin System Signaling’
09/01/10 - 09/01/16
Project Co-Leader; Core Leader
P50 CA136393 (Kaufmann - PI) National Cancer Institute Mayo Clinic Ovarian Cancer SPORE Title - “Project #4-Mechanism-guided development of an innovative therapy for ovarian cancer
1/1/11 - 11/10/15
Principle Investigator
Phase I/II Trial of the combination of the PARP inhibitor ABT-888 with floxuridine in epithelial ovarian, primary peritoneal and fallopian tube cancers
10/2011- Current
Principle Investigator
MC1012, Phase I study of the combination of the VEGFR inhibitor, AZD2171, and MEK inhibitor, AZD6244, in the treatment of solid malignancies
3/2011 - Current
Principle Investigator
N0733 “Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
8/2009 - Current
Foundation
Co-Principle Investigator
MNP #13.28 (Haluska and Kaufman) Minnesota Partnership for Biotechnology and Medical Genomics Genomic Approach for Targeted Immunotherapy Against Ovarian Cancer
03/01/14 – 2/28/16
Project Leader Ovarian Cancer Research Foundation - OCRF258797 Title- “The FA-BRCA pathway and response to platinum and PARP inhibitors in ovarian, tubal and peritoneal carcinomas.” Elizabeth Swisher- Overall PI
1/1/2013 - 1/1/2016
Industry
Program Director / Principal Investigator
TRIO 014 in: TRIO 014, A randomized, double-blind, placebo controlled, multi-center, phase II study of adding AMG 479 to first line chemotherapy in patients with optimally debulked (<1 cm) Epithelial ovarian cancer. Funded by Cancer International Research Group. (TRIO 014)
01/01/2010 - 12/31/2015
Program Director / Principal Investigator
MCR CD-ON-MEDI-573-1030: A Phase 1b/2 Randomized Study of MEDI-573 in Combination with an Aromatase Inhibitor (AI) Versus AI Alone in Women with Metastatic Breast Cancer (MBC). Funded by MedImmune, Inc. (Protocol Number CD-ON-MEDI-573-1030)
01/01/2012 - 12/31/2014
Program Director / Principal Investigator
Optimization of niraparib in the treatment of ovarian cancer. Funded by Tesaro.
10/01/2013 - 09/30/2015
Program Director / Principal Investigator
CO-338-017: A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Funded by Clovis. (Protocol CO-388-017)
12/01/2013 - 11/30/2015
Program Director / Principal
Evaluation of strategies to circumvent chemoresistance in ovarian Pdx trial. Funded by Genentech Incorporated.
12/06/2013 - 12/05/2015
Investigator
Program Director / Principal Investigator
BBI608-201, A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies. Funded by Boston Biomedical, Inc. (Protocol BB1608-201)
04/01/2014 - 03/31/2016
Completed Grants
Federal
Co-Investigator
R01 CA104378-04 Karnitz (PI) Therapeutic targeting of HSP90-dependent signaling
12/01/06 - 02/28/09
Awardee P50 CA 116201-03 Ingle (PI) Breast SPORE Career Development Award. Title: “Therapeutic Strategy for Targeting the Insulin-Like Growth Factor Receptor in Breast Cancer”.
09/2007 - 09/2009
Co-Investigator
Breast SPORE Developmental Research Project. Funded by National Institutes of Health. (P50 CA116201)
09/2005 - 08/2006
Awardee / Scholar
K12 CA090628-05 Hartmann (PI) Paul Calabresi/Mayo Clinical Oncology Research Training Program Title - “Targeting Minimal Residual Disease in Ovarian Cancer with Growth Factor Receptor Inhibition”.
7/1/2006 - 6/30/2010
Awardee P50 CA136393 (Hartmann - PI) National Cancer Institute Ovarian SPORE Career Development Award. Title: “Development and Application of Clinically Relevant In Vivo Models of Ovarian Cancer”.
12/1/09 - 12/1/11
Co-Principle Investigator (with Dr. Becker and Weroha)
P50 CA136393 (Hartmann - PI) National Cancer Institute Ovarian SPORE Developmental Award. Title: “Applying In Vivo Tumorgraft Models to Target Bowel Metastasis in Ovarian Cancer”.
10/1/2011 - 9/30/2012
Co-Principle Investigator (with Dr. Shridhar)
P50 CA136393 (Hartmann - PI) National Cancer Institute Ovarian SPORE Developmental Award. Title: “Mechanistic basis for drug synergy between metformin and inhibitors of IGF-R1/InsR in ovarian cancer”.
10/1/2011 - 9/30/2012
Co-Investigator
U01 CA069912-17 (Erlichman - PI) National Cancer Institute Phase I Clinical Trials of Anticancer Agents
03/01/11 - 02/28/13
Consultant Z1041 in: Z1041, A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed By Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Pts W/ Palpable & Operable Breast Cancer.
10/2007 - 09/2012
Foundation
Principle Investigator
Minnesota Ovarian Cancer Alliance Title- “Generation of Clinically Relevant Ovarian Cancer Xenograft Models.”
10/01/10 - 10/01/11
Project Director
Project 1: Haluska: Growth factor inhibition: IGF and HER systems in: Improving Therapeutic Outcomes for Ovarian Cancer. Funded by Andersen Foundation. (ANDERSEN #13 P-5)
12/2007 - 12/2010
Principal Investigator
Therapeutic implications of crosstalk between the IGF and HER system in ovarian cancer. Funded by Phi Beta Psi Sorority.
07/2006 - 06/2007
Project Director
Project 1-“Inhibition of the IGF Network in Ovarian Cancer”. Program Project Grant, Novel Therapeutics in Ovarian Cancer Andersen Foundation (Hartmann and Kaufmann Overall co-PIs)
01/01/06 - 01/01/09
Consultant P50-CA-58183, Neoadjuvant trial of lapatinib for the treatment of women with DCIS breast cancer in: Neoadjuvant trial of lapatinib for the treatment of women with DCIS breast cancer. Funded by Breast Cancer Research Foundation. (P50 BCRF)
10/2008 - 09/2010
Principal Investigator
Targeting Crosstalk between the Insulin-like growth factor I receptor and the HER family receptors in Breast Cancer. Funded by American Society of Clinical Oncology.
07/2006 - 06/2007
Mayo Clinic
Principal Investigator
CA 116201-03 Breast SPORE Career Development Award (Mayo Cancer Center Funds). Funded by Other Mayo. (P50 CA 116201)
09/2007 - 08/2008
Principal Investigator
Genetic Markers as Predictors of Toxicity in Patients Receiving Intraperitoneal Chemotherapy for Ovarian Carcinoma. Funded by Mayo Clinic.
05/2009 - 04/2010
Industry
Principal Investigator
Merck Onconet MCR MK-0646-027 Phase I Parallel Protocol of MK-0646 + MK-2206 and MK-0646 + MK-0752 Doublets
01/2011 - 01/2013
Principal Investigator
N0733 - Capecitabine + Lapatinib +/- IMC-A12 Collection Only Budget. Funded by GlaxoSmithKline. (N0733/111739)
04/2008 - 03/2012
Principal Investigator
N0733 - Capecitabine + Lapatinib +/- IMC-A12 Collection Only Budget. Funded by ImClone Systems Incorporated. (N0733)
04/2008 - 03/2012
Principal Investigator
Amendment #1(Replacement)IMCL CP13-0604 A Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With
04/2008 - 04/2012
Hormone Receptor-Positive Advanced or Metastatic Breast Cancer in: Amendment #1 (Replacement) IMCL CP13-0604 A Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced Metastatic Breast Cancer After Progression. Funded by ImClone Systems Incorporated. (IMCL CP13-0604)
Program Director / Principal Investigator
N0733 - Capecitabine + Lapatinib +/- IMC-A12 Collection Only Budget. Funded by ImClone Systems Incorporated. (NCCTG N0733)
04/01/2008 - 03/31/2010
Program Director / Principal Investigator
Amendment #1(Replacement)IMCL CP13-0604 A Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer in: Amendment #1 (Replacement) IMCL CP13-0604 A Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogensin Postmenopausal Women With Hormone Receptor-Positive Advanced Metastatic Breast Cancer After Progression. Funded by ImClone Systems Inclorporated. (IMCL CP13-0604)
04/04/2008 - 04/03/2010
Program Director / Principal Investigator
Changes in Estrogen-Responsive Breast Cancer In Response to Treatment with MK-0646 (IGF1R mAb) and MK-8669 (mTOR inhibitor). Funded by Merck & Co., Inc.
06/01/2009 - 05/31/2010
Program Director / Principal Investigator
MK646 correlative studies (Merck) in: Changes in Estrogen-Responsive Breast Cancer In Response to Treatment with MK-0646 (IGF1R mAb) and MK-8669 (mTOR inhibitor). Funded by Merck & Co., Inc.
06/01/2009 - 05/31/2010
Program Director / Principal Investigator
MK646 correlative studies (Merck) Aim #1 in: Changes in Estrogen-Responsive Breast Cancer In Response to Treatment with MK-0646 (IGF1R mAb) and MK-8669 (mTOR inhibitor). Funded by Merck & Co., Inc.
06/01/2009 - 05/31/2010
Program Director / Principal Investigator
MK646 correlative studies (Merck) Aims #3/5 in: Changes in Estrogen-Responsive Breast Cancer In Response to Treatment with MK-0646 (IGF1R mAb) and MK-8669 (mTOR inhibitor). Funded by Merck & Co., Inc.
06/01/2009 - 05/31/2010
Program Director / Principal Investigator
TRIO 015 in: TRIO 015 -Multicenter Open Label Phase II Study of Efficacy & Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type I Receptor...Ovarian Cancer. Funded by Cancer International Research Group. (MCCRC / TRIO 015)
08/01/2009 - 07/31/2011
Program Director / Principal Investigator
A4021040 “Phase I Safety and Tolerability Study of Figitumumab Combined with Pegvisomant in Patients with Advanced Solid Tumors”. Funded by Pfizer Inc. (Protocol A4021040)
08/03/2009 - 08/02/2011
PATENTS
Title Patent number Date filed Date issued
Diagnostic and therapeutic use of TOPORS US 2003176343 01/09/2003 09/18/2003
Inventors: Rubin, Eric H.; Saleem, Ahamed; Rasheed, Zeshaan; Haluska, Paul, Jr
BIBLIOGRAPHY
Peer-reviewed Articles
1. Li X-G, Haluska P, Hsiang YH, Bharti AK, Kufe DW, Liu LF, Rubin EH. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. Biochem Pharmacol 1997 Apr 4; 53(7):1019-27. PMID:9174116.
2. Haluska P, Saleem A, Edwards TK, Rubin EH. Interaction between the N-terminus of human
topoisomerase I and SV40 large T antigen. Nucleic Acids Res 1998 Apr 1; 26(7):1841-7. PMID:9512561. PMCID:PMC147454.
3. Ahmed F, Vyas V, Saleem A, Li X-G, Zamek R, Cornfield A, Haluska P, Ibrahim N, Rubin EH,
Gupta E. High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin. J Chromatogr B Biomed Sci Appl 1998 Apr 10; 707(1-2):227-33. PMID:9613954.
4. Gupta E, Toppmeyer D, Zamek R, Much J, Ibrahim N, Goodin S, Kane M, Aisner J, Li X-G,
Haluska P, Medina M, Cornfield A, Vyas V, Natelson E, Giovanella B, Saleem A, Rubin EH. Clinical evaluation of sequential topoisomerase targeting in the treatment of advanced malignancy. Cancer Therapeutics 1998 Nov-Dec; 1(5):292-301.
5. Haluska P, Saleem A, Rasheed Z, Ahmed F, Su EW, Liu L, Rubin EH. Interaction between
human topoisomerase I and a novel RING finger/arginine-serine protein. Nucleic Acids Res 1999 Jun 15; 27(12):2538-44. PMID:10352183. PMCID:PMC148458.
6. Haluska P, Adjei AA. Receptor tyrosine kinase inhibitors. Curr Opin Investig Drugs 2001;
2(2):280-286. PMID:11816845. 7. Dy GK, Haluska P, Adjei AA. Novel pharmacological agents in clinical development for solid
tumours. Expert Opin Investig Drugs 2001 Dec; 10(12):2059-88. PMID:11772306. 8. Haluska P, Dy GK, Adjei AA. Farnesyl transferase inhibitors as anticancer agents. Eur J
Cancer 2002 Sep; 38(13):1685-700. PMID:12175684. 9. Haluska P, Luetmer PH, Inwards CY, Afessa B, Shives TC, Ingle JN. Complications of therapy
and a diagnostic dilemma case of Case 3. Diagnostic dilemma: Sarcoidosis simulating metastatic malignancy. J Clin Oncol 2003 Dec 15; 21(24):4653-4. PMID:14673057.
10. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli
KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006 Jan 1; 66(1):362-71. PMID:16397250.
11. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet
M, Chianese D, Connely M, Terstappen LW, Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007 Jun 15; 13(12):3611-6. PMID:17575225.
12. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A,
Gualberto A, Adjei AA, de Bono JS. Phase 1 dose escalation study of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007 Oct 1; 13(19):5834-40. PMID:17908976.
13. Sekulic A, Haluska P Jr, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR,
Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN. Melanoma Study. Malignant melanoma in the 21st century: the emerging molecular landscape.
Mayo Clin Proc 2008 Jul; 83(7):825-46. PMID:18613999. PMCID:2739389. NIHMS:124777. 14. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, Sagar M, Wong TW, Gottardis
MM, Erlichman C. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008 Sep; 7(9):2589-98. Epub 2008 Sep 02. PMID:18765823. PMCID:PMC2614316. NIHMS:68744. DOI:10.1158/1535-7163.MCT-08-0493.
15. *Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials--early lessons. J Mammary
Gland Biol Neoplasia 2008 Dec; 13(4):471-83. Epub 2008 Nov 21. PMID:19023648. PMCID:PMC2728362. NIHMS:124775. DOI:10.1007/s10911-008-9104-6.
16. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN,
Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009 Apr 1; 69(7):2887-95. Epub 2009 Mar 10. PMID:19276366. PMCID:PMC2664865.
17. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg
PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody cp-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009 May 20; 27(15):2516-22. Epub 2009 Apr 20. PMID:19380445. DOI:10.1200/JCO.2008.19.9331.
18. Miller AJ, Markovic SN, Haluska P Jr. The pathway ahead in melanoma trials. Oncology
(Williston Park) 2009 May; 23(6):496, 498, 500. PMID:19544690. 19. *McKian KP, Haluska P. Cixutumumab. Expert Opin Investig Drugs 2009 Jul; 18(7):1025-33.
PMID:19548856. PMCID:PMC2939377. DOI:10.1517/13543780903055049. 20. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel
K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009 Nov; 4(11):1397-403. PMID: 19745765. PMCID:PMC2941876. DOI:10.1097/JTO.0b013e3181ba2f1d.
21. *Wahner Hendrickson AE, Haluska P, Schneider PA, Loegering DA, Peterson KL, Attar R,
Smith BD, Erlichman C, Gottardis M, Karp JE, Carboni JM, Kaufmann SH. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: Effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res 2009 Oct 1; 69(19): 7635-43. Epub 2009 Sep 29. PMID:19789352. PMCID:PMC2762725.
22. *Hendrickson AW, Haluska P. Resistance pathways relevant to insulin-like growth factor-1
receptor-targeted therapy. Curr Opin Investig Drugs 2009 Oct; 10(10):1032-40 PMID:19777391. PMCID in process.
23. Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth,
invasion, immune modulation, and implications for cancer therapeutics. Mayo Clin Proc 2009 Nov; 84(11):985-1000. PMID:19880689. PMCID:PMC2770910.
24. *Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN,
Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr MR, de Bono JS, Haluska P. Safety, pharmacokinetics, and preliminary activity of the anti-IGFR-IR antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010 Feb; 11(2):129-35. Epub 2009 Dec 23. PMID: 20036194. PMCID:PMC2941877. DOI:10.1016/S1470-2045(09)70354-7.
25. *Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy
SP, Haluska P. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or
cisplatin in patients with refractory solid tumors. Invest New Drugs 2011 June; 29(3); 473-80. Epub 2010 Jan 15. PMID:20082116. PMCID:PMC290718. DOI:10.1007/s10637-009-9381-y.
26. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barette BA, Kaur JS,
Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010 Feb 1; 70(3):875-82. Epub 2010 Jan 26. PMID:20103634. PMCID:PMC2890216. DOI:10.1158/0008-5472.CAN-09-2762.
27. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, de Bono
JS, Gualberto A, Hammer GD. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010 Mar; 65(4):765-73. Epub 2009 Aug 02. PMID:19649631. PMCID:PMC2875253. DOI:10.1007/s00280-009-1083-9.
28. Huntoon CJ ,Nye MD, Geng L, Peterson KL, Flatten KS, Haluska P, Kaufmann SH, Karnitz LM.
Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway. Cancer Res 2010 Nov 1;70(21):8642-50. Epub 2010 Sep 14. PMID:20841485. PMCID:PMC2970685. DOI:10.1158/0008-5472.
29. Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM, Ames MM.
Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer 2010 Sep; 17(3):623-36. Epub 2010 Jun 25. PMID:20385747. PMCID in process. DOI:10.1677/ERC-09-0318.
30. Haluska P. Insulin-like growth factor pathway. J Thorac Oncol 2010 Dec;5(12 Suppl 6):S478-9.
PMID:21102247. PMCID in process. DOI:10.1097/01.JTO.0000391374.71505.a2. 31. *Sirop SJ, Haluska P. Insulin-like growth factor pathway-targeted therapy in breast cancer.
Current Breast Cancer Reports 2011; 3(1):6-14. 32. *Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD,
Ross DD, Gottardis MM, Erlichman C, Kaufmann SH, Haluska P. Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924. Mol Cancer Ther. 2011
Jan;10(1):117-25. PMID:21220496. PMCID:PMC3057506. DOI:10.1158/1535-7163.
33. *Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr,
Keeney GL, Peethambaram PP, Haluska P. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol 2011 Jul;122(1):116-20. Epub 2011 Apr 22. PMID: 21514634. PMCID:PMC3104066. DOI:10.1016/j.ygyno.2011.03.030.
34. *Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman
C, Haluska P. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Invest New Drugs 2012 Oct;30(5):1934-41. Epub 2011 Sep 1. PMID:21881915. DOI: 10.1007/s10637-011-9742-1.
35. *Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Finckenstein F, Brodie A, Gottardis
MM, Carboni JM, Haluska P. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res. 2011 Dec 15; 71(24):7597-607. Epub 2011 Oct 31. PMID:22042792. PMCID in process. DOI:10.1158/0008-5472.
36. O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R,
Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol 2012 Mar;
69(3):605-12. Epub 2011 Sep 22. PMID:21938545. PMCID in process. DOI:10.1007/s00280-011-1733-6.
37. *Wahner Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-
Otero G, Erlichman C, Ivy P, Kaufmann SH, Karnitz LM, Haluska P. A Phase II Study of Gemcitabine in Combination with Tanespimycin in Advanced Epithelial Ovarian and Primary Peritoneal Carcinoma. Gynecol Oncol 2012 Feb; 124(2):210-5. Epub 2011 Nov 1. PMID:22047770. PMCID:PMC3265019. DOI:10.1016/j.ygyno.2011.
38. *Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM,
Gottardis MM, Haluska P. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res 2012 Mar 15;18(6):1808-17. Epub 2012 Jan 27. PMID:22287600. PMCID:PMC3306532. DOI:10.1158/1078-0432.CCR-11-1806.
39. *Weroha SJ, Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin
North Am 2012 Jun; 41(2):335-50. PMID:22682634. PMCID:PMC3614012. DOI:10.1016/j.ecl.2012.04.014.
40. Holtan SG, Mansfield AS, Creedon DJ, Nevala WK, Haluska P, Leontovich AA, Markovic SN.
An organ system based approach to prognosis in advanced melanoma. Front Biosci (Elite Ed) 2012 Jun 1; 4:2823-33. PMID:22652681. PMCID in process.
41. *Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying Insulin
Receptor Isoform Expression in FFPE Breast Tumors. Growth Horm IGF Res 2012 Jun-Aug; 22(3-4):108-15. PMID:22551578. PMCID:PMC3392524. DOI:10.1016/j.ghir.2012.04.001.
42. *Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G.
Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol 2012 Feb; 124(2):210-5. PMID:22047770. PMCID:PMC3265019. DOI:10.1016/j.ygyno.2011.10.002.
43. *Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM,
Gottardis MM, Haluska P. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res 2012 Mar 15; 18(6):1808-17. Epub 2012 Jan 27. PMID:22287600. PMCID:PMC3306532. DOI:10.1158/1078-0432.CCR-11-1806.
44. *Weroha SJ, Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin
North Am 2012 Jun; 41(2):335-50, vi. PMID:22682634. PMCID:PMC3614012. DOI:10.1016/j.ecl.2012.04.014.
45. *Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying insulin
receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res. 2012 Jun-Aug; 22(3-4):108-15. Epub 2012 Apr 30. PMID:22551578. PMCID:PMC3392524. DOI:10.1016/j.ghir.2012.04.001.
46. Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P, Oesterreich S. Hormone response
in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer 2012 Dec; 19(6):R255-79. Epub 2012 Nov 09. PMID:23045324. PMCID:PMC3696394. DOI:10.1530/ERC-12-0175.
47. Liang JJ, Kizilbash SH, Haluska P. Intrathecal metastases causing conus medullaris syndrome.
QJM 2013 Jan 21. [Epub ahead of print] PMID:23340390. DOI:10.1093/qjmed/hct008.
48. Demichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Jo Chien A, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials. Clin Cancer Res 2013 Jun 1; 19(11):2817-23. Epub 2013 Mar 7. PMID:23470967.
DOI:10.1158/1078-0432.CCR-12-2620. 49. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A,
Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol 2012 Dec 20; 30(36):4584-6; author reply 4588-9. Epub 2012 Nov 19. PMID:23169510. DOI:10.1200/JCO.2012.44.1022.
50. Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z,
Chen HX, Erlichman C, Ellis MJ, Fleming GF. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 2013 May; 139(1):145-53. Epub 2013 Apr 19. PubMed PMID: 23605083. DOI:10.1007/s10549-013-2528-8.
51. Chae YK, Hu MI, Katz RL, Chavez-Macgregor M, Haluska P, Meric-Bernstam F, Gonzalez-
Angulo AM, Melhem-Bertrandt A. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol 2013 Aug 10; 31(23):e398-400. Epub 2013 Jun 24. PMID:23796991. DOI:10.1200/JCO.2012.46.6383.
52. Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB,
Stack MS. Epithelial ovarian cancer experimental models. Oncogene 2013 Aug 12. [Epub ahead of print] PMID:23934194. DOI:10.1038/onc.2013.321.
53. *Becker MA, Farzan T, Harrington SC, Krempski JW, Weroha SJ, Hou X, Kalli KR, Wong TW, Haluska P. Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth. Mol Cancer Ther. 2013 Dec;12(12):2909-16. Epub 2013 Oct 15. PMID:24130056 PMCID:PMC3880137
54. Scott CL, Mackay HJ, Haluska P Jr. Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book. 2014; 34:e258-66. PMID:24857111
55. *Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res. 2014 Mar 1;20(5):1288-97. PMID:24398046 PMCID:PMC3947430
56. King H, Aleksic T, Haluska P, Macaulay VM. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev. 2014 Aug 4. PMID:25123819
57. Haluska P, Menefee ME, Plimack ER, Rosenberg JE, Northfelt DW, LaVallee T, Shi L, Yu XQ,
Burke PA, Huang J, Viner J, McDevitt J, LoRusso PM. Phase I Dose Escalation Study of MEDI-573, a Bispecific, Anti-ligand Monoclonal Antibody against IGF-I and IGF-II, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2014 Jul 14. [Epub ahead of print] PMID:25024259
58. Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S,
Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014 Jul 10. pii: S0090-8258(14)01070-1. [Epub ahead of print] PMID:25016924
59. Scott CL, Mackay HJ, Haluska P Jr. Patient-derived xenograft models in gynecologic
malignancies. Am Soc Clin Oncol Educ Book. 2014:e258-66. PMID: 24857111
60. Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss
M, Adams PT, Dockter TJ, Loprinzi CL; Alliance for Clinical Trials in Oncology. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of
http://www.ncbi.nlm.nih.gov/pubmed?term=Rosenberg%20JE%5BAuthor%5D&cauthor=true&cauthor_uid=25024259
http://www.ncbi.nlm.nih.gov/pubmed?term=Northfelt%20DW%5BAuthor%5D&cauthor=true&cauthor_uid=25024259
paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014 Jun 15;120(12):1890-7. doi: 10.1002/cncr.28654. Epub 2014 Mar 11. PMID:24619793[PubMed - in process] PMCID:PMC4047184
61. Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014 Mar;73(3):467-73. doi: 10.1007/s00280-013-2372-x. Epub 2014 Jan 4.
62. Reid JM, Goetz MP, Buhrow SA, Walden C, Safgren SL, Kuffel MJ, Reinicke KE, Suman V, Haluska P, Hou X, Ames MM. Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies. Cancer Chemother Pharmacol. 2014 Dec;74(6):1271-8. doi: 10.1007/s00280-014-2605-7. Epub 2014 Oct 16. PubMed PMID: 25318936.
63. Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM,Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497. Epub 2014 Oct 7. PubMed PMID: 25290091; PubMed Central PMCID: PMC4229637.
64. Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 2015 Jan 1;75(1):22-30. doi: 10.1158/0008-5472.CAN-14-2533. Epub 2014 Nov 14. PubMed PMID: 25398436.
65. *Becker MA, Haluska P, Bale LK, Oxvig C, Conover CA. A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts. Mol Cancer Ther. 2015 Feb 18. pii: molcanther.0880.2014. [Epub ahead of print] PubMed PMID: 25695953.
66. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, Van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24. PubMed PMID: 25712686; PubMed Central PMCID: PMC4490043.
67. Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC). TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15;21(12):2722-9. doi:10.1158/1078-0432.CCR-14-2780. Epub 2015 Mar 16. PubMed PMID: 25779953.
68. *Lodhia KA, Hadley AM, Haluska P, Scott CL. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta. 2015 Apr;1855(2):223-234. doi: 10.1016/j.bbcan.2015.03.002. Epub 2015 Mar 14. Review. PubMed PMID: 25783201; PubMed Central PMCID: PMC4433556.
69. *Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. PLoS One. 2015 May 11;10(5):e0126867. doi: 10.1371/journal.pone.0126867. eCollection 2015. PubMed PMID: 25962155; PubMed Central PMCID: PMC4427104.
70. *Lodhia KA, Tienchaiananda P, Haluska P. Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment. Front Oncol. 2015 Jul 8;5:142. doi:10.3389/ fonc.2015.00142. eCollection 2015. Review. PubMed PMID: 26217584; PubMed Central PMCID: PMC4495315.
Non-peer-reviewed Articles 71. Li X-G, Haluska P, Hsiang YH, Bharti A, Kufe DW, Rubin EH. Identification of topoisomerase I
mutations affecting both DNA cleavage and interaction with camptothecin. Ann N Y Acad Sci 1996 Dec 13; 803:111-27. PMID:8993505
72. Haluska P, Rubin EH. A role for the amino terminus of human topoisomerase I. Adv Enzyme
Regul 1998; 38:253-62. PMID:9762357. 73. Haluska P, Rubin E, Verschraegen CF. Topoisomerase-I inhibitors in gynecologic tumors.
Hematol Oncol Clin North Am 1999 Feb; 13(1):43-61, vii-viii. PMID:10080069. Editorials 74. Miller AJ, Markovic SN, Haluska P Jr. The pathway ahead in melanoma trials. Oncology
(Williston Park) 2009 May; 23(6): 496, 498, 500. PMID:19544690. 75. Wahner-Hendrickson AE, Haluska P, Erlichman C, Gottardis M, Carboni JE, Karp JE,
Kaufmann SH. Insulin Receptor A and IGF-IR in AML – Response. Cancer Res 2010 Sep 1; 70(17):7011. Epub 2010 Aug 10. PMID:20699368.
Abstracts and Letters 76. Toppmeyer D, Haluska P, Li X-G, Goodin S, Orlick M, Aisner J, Rubin EH. Sequential
camptothecin and etoposide in the treatment of refractory malignancies. Annual Retreat on Cancer Research. Princeton, New Jersey. 05/31/1996. (Abstract)
77. Saleem A, Toppmeyer D, Gupta E, Zamek R, Much J, Ibrahim N, Bindi M, Haluska P, Li X-G, Goodin S, Aisner J, Natelson E, Giovanella B, Rubin EH. Analysis of topoisomerase I and II protein levels in a clinical trial of sequential camptothecin and etoposide. Poster Presentation. The Seventh Conference on DNA Topoisomerases in Therapy- NYU Medical Center and The Kaplan Cancer Center. 10/21/1996 - 10/24/1996. (Abstract)
78. Toppmeyer D, Gupta E, Saleem A, Zameck R, Much J, Ibrahim N, Bindi H, Haluska P, Li XG, Goodin S, Aisner J, Natelson N, Giovanella B, Rubin EH. A Phase I Pharmacokinetic and Pharmacodynamic Study of Camptothecin and Etoposide in Patients with Advanced Malignancies. Annual Retreat on Cancer Research. Princeton, New Jersey. 05/30/1997. (Abstract)
79. Rasheed Z, Haluska P, Saleem A, Rubin EH. Identification of a novel protein that binds to human topoisomerase I. Poster Presentation. 1999 AACR Annual Meeting. 04/10/1999-04/14/1999. (Abstract)
80. Allen RD, Haluska P, Bergstrom L. Non-surgical Free Intraperitoneal Air. Minnesota American College of Physician Annual Meeting. Bloomington, Minnesota. 10/25/2002. (Abstract)
81. Allen RD, Haluska P, Bergstrom L. Postinfectious Glomerulonephritis & Furosemide-Induced Interstitial Nephritis. Minnesota American College of Physician Annual Meeting. Bloomington, Minnesota. 10/25/2002. (Abstract)
82. Saulnier MG, Velaparthil U, Frennesson1 DB, Liu P, Zimmermann K, Sang X, Eummer J, Bedingfield K, Lee FT, Carboni JM, Vyas DM, Haluska P, Loegering DA, Kaufmann SH, Erlichman C, Attar R, Gottardis G, Wittman M. SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one inhibitors of the IGF-1 receptor kinase with in vivo antitumor activity. Proceedings of the 229th National Meeting of the American Chemical Society. San Diego, California. 03/13/2005 - 03/17/2005. (Abstract)
83. Wahner Hendrickson AE, Karp JE, Carboni J, Attar RM, Smith BD, Whittman M, Gottardis M, Haluska PJ, Kaufmann SH. . Apoptotic and anti-proliferative effects of the dual insulin-like growth factor-1(IGF-1R)/insulin receptor inhibitor, BMS 536924, in acute myelogenous leukemia. Poster Presentation. 2007 AACR Annual Meeting. Los Angeles, California. 04/14/2007 - 04/18/2007. (Abstract)
84. de Bono JS, Adjei A, Attard G, Pollak M, Fong P, Haluska P, Roberts L, Chainese D, Terstappen L, Gualberto A. Circulating tumor cells expressing the insulin growth factor-1 receptor (IGF-1R); Method of detection, incidence and potential applications. Oral Presentation. 2007 ASCO Annual Meeting. Chicago, Illinois. 06/01/2007 - 06/05/2007. (Abstract)
85. Santisebant M, Reiman JM, Behrens MD, Haluska P, Mukherjee P, Bhattacharya R, Ferrone S, Kalli KR, Knutson KL. Immunoedited breast tumor cells demonstrate characteristics of both mesenchymal and cancer stem cells. J Immunother. 2007 Nov-Dec; 30(8):889-90. (Abstract)
86. Olmos D, Molife R, Okuno S, Worden F, Hammer G, Yap T, Shaw H, Schuetze S, Roberts L, Gualberto A, De-Bono J, Haluska P. Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CIP-751,871 in patients with sarcomas and achrenocortical tumors. Mol Cancer Ther 2007 Dec; 6(12):3355S. (Abstract)
87. Haluska P, Stensgard BA, Qin R, Felton SJ, Batzel GN, Ivy SP, Toft DO, Erlichman C. Phase I study of 17-allylamino-17 demethoxygeldanamycin (17-AAG), gemcitabine (Gem) and/or cisplatin (CDDP) in solid tumor patients. Ann Oncol. 2008; 19(Suppl 3):34. (Abstract)
88. Gualberto A, Melvin CL, Dean A, Ang AL, Reynolds JM, Lee AV, Terstappen LW, Haluska P,
Lipton A, Karp DD. Characterization of NSCLC patients responding to anti-IGF-IR therapy. Oral Presentation. 2008 ASCO Annual Meeting. Chicago, Illinois. 05/30/2008 - 06/03/2008. (Abstract)
89. Karp DD, Paz-Ares LD, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Gualberto A, Langer CJ. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. Oral Presentation. 2008 ASCO Annual Meeting. Chicago, Illinois. 05/30/2008 - 06/03/2008. (Abstract)
90. Olmos D, Okuno S, Schuetz SM, Paccagnella ML, Yin D, Gualberto A, Worden FP, Haluska P, De Bono JS, Scurr M. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. 2008 ASCO Annual Meeting (oral presentation). Chicago, IL. 2008 May 30-Jun 3. (Abstract)
91. Yin D, Paccagnella ML, Lacy MQ, De Bono JS, Haluska P, Gualberto A, Sharma A. Population pharmacokinetics of CP-751,871, a monoclonal antibody against IGF-1 receptor, in patients with multiple myeloma or solid tumors. Poster Discussion Presentation. 2008 ASCO Annual Meeting. Chicago, Illinois. 05/30/2008 - 06/03/2008. (Abstract)
92. Gualberto A, Melvin CL, Dean A, Ang AL, Reynolds J, Lee AV, Terstappen LW, Haluska P, Lipton A, Karp DD. Igf-Ir markers in NSCLC patients on anti-Igf-Ir therapy. Ann Oncol 2008 Sep; 19(Suppl 8):62. (Abstract)
93. Karp DD, Paz-Ares L, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Gualberto A, Langer C. Addition of Cp-751,871, an anti-Igf-Ir antibody, to paclitaxel and carboplatin results in high activity in non-small cell lung cancer (Nsclc), particularly in the squamous subtype. Ann Oncol 2008 Sep; 19(Suppl 8):90. (Abstract)
94. Haluska P, Carboni JM, Asmann YW, Ten Eyck C, Allar RM, Tibodeau JD, Hou X, Nakanishi T, Ross DD, Kaufmann SH, Gottardis MM, Erlichman C. Drug efflux by breast cancer resistance protein (BCRP) is a mechanism of resistance to the insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Cancer Res 2008 Jan; 69(2 Suppl S):200S. (Abstract)
95. *Harrington S, Hou X, Macedo L, Weroha J, Brodie A, Haluska P. Insulin Receptor A isoform and erbB receptor up-regulated in response to IGF-1R targeted therapy. Poster Presentation. Gordon Research Conference. Ventura, California. 03/22/2009 - 03/27/2009. (Abstract)
96. *Hou X Carboni J Macedo L Harrington S Finckenstein F Brodie A Gottardis M, Haluska P. Combined estrogen signaling inhibition and IGF-1R/InsR inhibition with BMS-754807 in estrogen dependent breast cancer model has synergistic antitumor activity in vitro and in vivo. Poster Presentation. 100th Annual AACR Meeting 2009. Denver, Colorado. 04/18/2009 - 04/22/2009. (Abstract)
97. *Hou X, Harrington S, Macedo L, Weroha J, Brodie A, Haluska P. Hormonal therapies differentially enhance insulin receptor isoform A and erbB receptor up-regulation in response to IGF-1R inhibitor MK-0646 in vivo. Poster Presentation. 100th Annual AACR Meeting 2009. Denver, Colorado. 04/18/2009 - 04/22/2009. (Abstract)
98. Haluska P, Oberg AL, Dakhil SR, Ziegler KLA, Rowland KM, Hartmann LC, Moore DF, Keeney GL, Peethambaram PP. Phase II trial of lapatinib in combination with weekly topotecan in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Ann Oncol 2009 May; 20:43. (Abstract)
99. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GNW, Paccagnella ML, De Bono JS, Gualberto A, Hammer GD. Safety, tolerability, and pharmacokinetics of the anti-IgF-1R monoclonal antibody CP-751,871 in patients with refractory adrenocortical carcinoma. Ann Oncol 2009 May; 20:42. (Abstract)
100. Karp DD, Novello S, Cardenal F, Haluska P, Blakely LJ, Garland L, Paz-Ares LG, Dolled-Filhart MP, Johnson ED, Gualberto A. Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol 2009 May 20; 27(Suppl S):8072. (Abstract)
101. Haluska P, Hou X, Huang F, et al. Complete IGF Signaling Blockade by the Dual-Kinase Inhibitor, BMS-754807, Is Sufficient To Overcome Tamoxifen and Letrozole Resistance In Vitro and In Vivo. Cancer Res 2009;69(24 Suppl):Abstract nr 402 (Abstract)
102. Haluska P, Harrington SC, Farzan T, Winterhoff BJ, Goodman KM, Kalli KK, Gottfried KE. Low expression of insulin-like growth factor binding proteins predicts poor outcomes in ovarian cancer patients. AACR/JCA Joint Conference: Genomics, Epigenomics, and the Development of Novel Therapeutics. Waikoloa, Hawaii. 2010 Feb 6. (Abstract)
103. Haluska P, Reinholz MM, Dueck AC, Linden HM, Lingle WL, Bernath AM, Arbushites MC, Youssoufian H, Chen HX, Perez EA. N0733: Phase II Trial of Capecitabine and Lapatinib +/- Cixutumumab in HER2 Positive Breast Cancer. [Abstract #TPS129]. J Clin Oncol 2010 May; 28(15s):14s. (Abstract)
104. Erlichman C, Menefee ME, Northfelt DW, Qin R, Reid JM, Oursler M, Marks R, Molina JR, Haluska P, Koch K. Phase I trial of dasatinib (D) and lapatinib (L). J Clin Oncol 06/07/2010; 28(15s (abstr 2610)). (Abstract)
105. Menefee ME, LoRusso P, Viner J, McDevitt J, Huang W, Lam B, Jin F, Chang Y, Haluska P. MEDI-573, a dual IGF-1/-2 neutralizing antibody, blocks IGF-1R and IR-A signaling and maintains glucose homeostasis in a Phase 1 study for advanced solid tumors. 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics," Berlin, Germany Nov 16-19 2010. (Oral - Plenary Session)
106. *Becker M, Hou X, Harrington SC, Carboni JM, Gottardis MM, Haluska P. IGFBP5 confers
resistance to IGF targeting and correlates with increased invasion and poor overall survival in breast tumors. Gordon Conference: Insulin-Like Growth Factors in Physiology & Disease, Ventura, CA Feb 27-Mar 4, 2011. (Oral - Selected Presentation)
107. Haluska P, Dhar A, Hou X, Huang F, Nuyten DSA, Park JS, Brodie AH, Ingle JN, Carboni JM,
Gottardis MM, Wolff AC, Finckenstein FG. Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. Trials in Progress, 2011 ASCO Annual Meeting, Chicago, Illinois, June 3-7, 2011. (Poster Presentation)
108. Haluska P, Hou X, Dhar A, Yee D, Suman VJ, Harrington SC, Finckenstein F, Ingle JN.
Regulation of Hormone-resistant Breast Cancer by IGF and Insulin System Signaling. Poster Discussion, NCI Translational Science Meeting 2011, Washington, DC, July 28-29.
109. P. Haluska, J. Huang, B. Lam, X. Chen, W. Huang, P. LoRusso, M.E. Menefee, T. LaVallee, Y.
Yao, J. Viner. MEDI-573--a novel approach to IGF-1R and IR-A signaling inhibition by blocking IGF ligands: Phase 1 PK/PD, safety data, and disease linkage studies in breast cancer. ASCO Breast Cancer Symposium, San Francisco, CA, Sept 8-10, 2011. (Poster and Oral Presentation)
110. Farzan T, Harrington S, Krempski J, Weroha S, Hou X, Kalli K, Haluska P. Combined
erbB/VEGFR blockade has improved anticancer activity over single-pathway inhibition in ovarian cancer in vivo. Gynecol Oncol. 2011 Mar; 121(Suppl 1):S45.
111. Winterhoff B, Haluska P, Kalli K, Cliby W, Gostout B, Oberg A, Maurer M, Hartmann L, Slamon
D, Konecny G. Insulin-like growth factor receptor 1 pathway signature correlates with adverse clinical outcome in ovarian cancer. Gynecol Oncol. 2011 Mar; 121(Suppl 1):S71-2.
112. Haluska P, Dudek AZ, Bono P, Sleight B, Joensuu H, Juergens H, Pollak M. Phase I trial of
figitumumab and pegvisomant in patients with advanced solid tumors. Ann Oncol. 2011 May; 22(Suppl 3):39.
113. Haluska P, Oberg AL, Glaser G, Gonzalez SE, Becker MA, Jacob KA, Pennil CC, Fink SR, Kalli
KR, Swisher EM, Jenkins RB, Sarkaria JN, Karlan BY, Weroha SJ. Ovarian avatar project: a model system for individualizing ovarian cancer therapy. Ann Oncol. 2012 Mar; 23:42.
114. Butler K, Weroha S, Beckre M, Enderica-Gonzalez S, Harrington S, Hou X, Visscher D,
Haluska P. Ovarian cancer tumorgraft: viral latency propagates lymphoma. Genecol Oncol. 2012 Oct; 127(1):S16.
115. Haluska P, Menefee ME, Plimack ER, Rosenberg JE, Northfelt DW, LaVallee T, Huang W, Yu
XQ, Viner JL, LoRusso P. A phase 1 study of medi-573, an investigational monoclonal antibody that targets IGF-I and IGF-II: safety, pharmacokinectics, and antitumor activity in adults with advanced solid tumors. Eur J Cancer. 2012 Nov; 48:187-8.
116. Weroha SJ, Haluska P, Becker MA, Harrington SC, Goodman KM, Gonzalez SE, al Hilli M,
Butler KA, Kalli KR, Oberg AL. Ovarian avatar models predictive of platinum response in ovarian cancer patients. Ann Oncol. 2013 Mar; 24:16.
117. Galanis E, Atherton P, Dowdy S, Cliby W, Haluska P, Long H, Aderca I, Knutson K, Block M,
Federspiel M, Russell S, Peng KW, Hartmann L. Intraperitoneal (ip) administration of an oncolytic measles virus (mv) strain expressing the sodium iodine symporter gene in patients (pts) with advanced ovarian cancer (ovca). Mol Ther. 2013 June; 21LS6-7.
* Indicates that the primary author was a mentee of this author.
